targeted Therapies
With no Compromise

PDC Therapeutics is a clinical-stage biotechnology start-up developing smart nanomedicines for targeted therapies.

Superior Therapeutic Index

Sagitta® biodegradable conjugation platforms are discovered to reinforce ideal performances in terms of the therapeutic index, pharmacokinetics and manufacturability.
Read More
targeted Therapies With no Compromise

PDC Therapeutics is a clinical-stage biotechnology start-up developing smart nanomedicines for targeted therapies.

Superior Therapeutic Index

Sagitta® biodegradable conjugation platforms are discovered to reinforce ideal performances in terms of the therapeutic index, pharmacokinetics and manufacturability.

Read More

PDC Therapeutics announces online abstract acceptance at ASCO Annual Meeting 2025

PDC Therapeutics, a biotech company developing targeted Polymer-Drug Conjugate technologies…

Publications

PDC Therapeutics Co-Founder Prof. Rana Sanyal won the European Prize for Women Innovators

PDC Therapeutics Co‑Founder Prof. Rana Sanyal wins the 2024 European Women Innovators Award

Latest News

Building better docetaxel therapy with nanocarrier technology, covered by BioWorld

PDC Therapeutics SA has passed the first test of its novel nanocarrier technology…

News on the Media